FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 701 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with... March 3, 2026 EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride August 4, 2022 Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... March 1, 2019 EMA Recommends Extension of Indications for Atezolizumab September 28, 2020 Load more HOT NEWS A Congress Bag for Women’s Empowerment How Can Hormone Replacement Therapy for Menopause Impact My Cancer Risk? Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node... EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris
